minocycline hydrochloride · Journey · NDA 201922
Ximino
Earliest generic entry, as listed · earliest of 5 marketed strengths
2 Apr 2027
2 of 5 marketed strengths have no unexpired patent or exclusivity listed; no marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7541347, US 7544373.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7541347 | use U-917 · sets the listed date | 2 Apr 2027 |
| US 7544373 | drug product · sets the listed date | 2 Apr 2027 |
| US 7919483 | use U-124 | 7 Mar 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Enters 12-month window basis: patent · 201922-005Listed date 2 Apr 2027Detected 24 Oct 2026
- Enters 12-month window basis: patent · 201922-003Listed date 2 Apr 2027Detected 24 Oct 2026
- Enters 12-month window basis: patent · 201922-001Listed date 2 Apr 2027Detected 24 Oct 2026
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 201922 · 001 · discontinued | capsule, extended release, oral | EQ 45MG BASE | 2 Apr 2027 |
| 201922 · 002 · discontinued | capsule, extended release, oral | EQ 67.5MG BASE | open |
| 201922 · 003 · discontinued | capsule, extended release, oral | EQ 90MG BASE | 2 Apr 2027 |
| 201922 · 004 · discontinued | capsule, extended release, oral | EQ 112.5MG BASE | open |
| 201922 · 005 · discontinued | capsule, extended release, oral | EQ 135MG BASE | 2 Apr 2027 |